Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Mar 6;90(10):464-471. doi: 10.1212/WNL.0000000000005055. Epub 2018 Feb 9.

PMID:
29440566
2.

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias.

Figueroa KP, Gan SR, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Pulst SM, Kuo SH.

Mov Disord. 2018 Mar;33(3):497-498. doi: 10.1002/mds.27258. Epub 2017 Nov 29. No abstract available.

PMID:
29193335
3.

Dystonia and ataxia progression in spinocerebellar ataxias.

Kuo PH, Gan SR, Wang J, Lo RY, Figueroa KP, Tomishon D, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

PMID:
29089256
4.

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.

Gan SR, Wang J, Figueroa KP, Pulst SM, Tomishon D, Lee D, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2017 Oct 9;7:492. doi: 10.7916/D8GM8KRH. eCollection 2017.

5.

The evolving genetic risk for sporadic ALS.

Gibson SB, Downie JM, Tsetsou S, Feusier JE, Figueroa KP, Bromberg MB, Jorde LB, Pulst SM.

Neurology. 2017 Jul 18;89(3):226-233. doi: 10.1212/WNL.0000000000004109. Epub 2017 Jun 22.

6.

Genetic analysis of age at onset variation in spinocerebellar ataxia type 2.

Figueroa KP, Coon H, Santos N, Velazquez L, Mederos LA, Pulst SM.

Neurol Genet. 2017 May 15;3(3):e155. doi: 10.1212/NXG.0000000000000155. eCollection 2017 Jun.

7.

Gene co-expression network analysis for identifying modules and functionally enriched pathways in SCA2.

Pflieger LT, Dansithong W, Paul S, Scoles DR, Figueroa KP, Meera P, Otis TS, Facelli JC, Pulst SM.

Hum Mol Genet. 2017 Aug 15;26(16):3069-3080. doi: 10.1093/hmg/ddx191.

PMID:
28525545
8.

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.

Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM.

Nature. 2017 Apr 20;544(7650):362-366. doi: 10.1038/nature22044. Epub 2017 Apr 12.

PMID:
28405024
9.

Estimation of life expectancy of patients diagnosed with the most common cancers in the Valparaiso Region, Chile.

Taramasco C, Figueroa K, Lazo Y, Demongeot J.

Ecancermedicalscience. 2017 Jan 17;11:713. doi: 10.3332/ecancer.2017.713. eCollection 2017.

10.

The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.

Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2017 Jun;16(3):615-622. doi: 10.1007/s12311-016-0836-3.

11.

Population-based risks for cancer in patients with ALS.

Gibson SB, Abbott D, Farnham JM, Thai KK, McLean H, Figueroa KP, Bromberg MB, Pulst SM, Cannon-Albright L.

Neurology. 2016 Jul 19;87(3):289-94. doi: 10.1212/WNL.0000000000002757. Epub 2016 May 11.

12.

Spontaneous shaker rat mutant - a new model for X-linked tremor/ataxia.

Figueroa KP, Paul S, Calì T, Lopreiato R, Karan S, Frizzarin M, Ames D, Zanni G, Brini M, Dansithong W, Milash B, Scoles DR, Carafoli E, Pulst SM.

Dis Model Mech. 2016 May 1;9(5):553-62. doi: 10.1242/dmm.022848. Epub 2016 Mar 24.

13.

Two different genetic diseases in the same patient: Coincident, concomitant, or causally related?

Graf J, Hellenbroich Y, Veelken N, Figueroa KP, Wolff S, Pulst S, Brüggemann N.

Mov Disord. 2016 Apr;31(4):491-2. doi: 10.1002/mds.26539. Epub 2016 Feb 22. No abstract available.

PMID:
26900085
14.

Co-expression networks in generation of induced pluripotent stem cells.

Paul S, Pflieger L, Dansithong W, Figueroa KP, Gao F, Coppola G, Pulst SM.

Biol Open. 2016 Feb 18;5(3):300-10. doi: 10.1242/bio.016402.

15.

Depression and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Yu JT, Lee LE, Ashizawa T, Subramony SH, Kuo SH.

Parkinsonism Relat Disord. 2016 Jan;22:87-92. doi: 10.1016/j.parkreldis.2015.11.021. Epub 2015 Nov 22.

16.

Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model.

Dansithong W, Paul S, Figueroa KP, Rinehart MD, Wiest S, Pflieger LT, Scoles DR, Pulst SM.

PLoS Genet. 2015 Apr 22;11(4):e1005182. doi: 10.1371/journal.pgen.1005182. eCollection 2015 Apr.

17.

Vascular risk factors and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 2;5:287. doi: 10.7916/D89885S0. eCollection 2015.

18.

OHEP: an oral health education program for mothers of newborns.

Hallas D, Fernandez JB, Lim LJ, Catapano P, Dickson SK, Blouin KR, Schmidt TM, Acal-Jiminez R, Ali N, Figueroa KE, Jiwani NM, Sharma A.

J Pediatr Health Care. 2015 Mar-Apr;29(2):181-90. doi: 10.1016/j.pedhc.2014.11.004. Epub 2014 Dec 26.

PMID:
25547319
19.

Coenzyme Q10 and spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Mov Disord. 2015 Feb;30(2):214-20. doi: 10.1002/mds.26088. Epub 2014 Dec 1.

20.

Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Neuenschwander AG, Thai KK, Figueroa KP, Pulst SM.

JAMA Neurol. 2014 Dec;71(12):1529-34. doi: 10.1001/jamaneurol.2014.2082. Erratum in: JAMA Neurol. 2015 Jan;72(1):128.

21.

Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study.

Moscovich M, Okun MS, Favilla C, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai V, Ying S, Zesiewicz T, Kuo SH, Mazzoni P, Bushara K, Xia G, Ashizawa T, Subramony SH.

J Neuroophthalmol. 2015 Mar;35(1):16-21. doi: 10.1097/WNO.0000000000000167.

22.

Effects of manual task complexity on gait parameters in school-aged children and adults.

Abbruzzese LD, Rao AK, Bellows R, Figueroa K, Levy J, Lim E, Puccio L.

Gait Posture. 2014 Sep;40(4):658-63. doi: 10.1016/j.gaitpost.2014.07.017. Epub 2014 Jul 28.

PMID:
25168911
23.

Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes.

Tezenas du Montcel S, Durr A, Bauer P, Figueroa KP, Ichikawa Y, Brussino A, Forlani S, Rakowicz M, Schöls L, Mariotti C, van de Warrenburg BP, Orsi L, Giunti P, Filla A, Szymanski S, Klockgether T, Berciano J, Pandolfo M, Boesch S, Melegh B, Timmann D, Mandich P, Camuzat A; Clinical Research Consortium for Spinocerebellar Ataxia (CRC-SCA); EUROSCA network, Goto J, Ashizawa T, Cazeneuve C, Tsuji S, Pulst SM, Brusco A, Riess O, Brice A, Stevanin G.

Brain. 2014 Sep;137(Pt 9):2444-55. doi: 10.1093/brain/awu174. Epub 2014 Jun 26.

24.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group.

Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22.

PMID:
24965700
25.

Familial clustering of ALS in a population-based resource.

Gibson SB, Figueroa KP, Bromberg MB, Pulst SM, Cannon-Albright L.

Neurology. 2014 Jan 7;82(1):17-22. doi: 10.1212/01.wnl.0000438219.39061.da. Epub 2013 Dec 4.

26.

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.

Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony SH.

Orphanet J Rare Dis. 2013 Nov 13;8:177. doi: 10.1186/1750-1172-8-177.

27.

Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Tazen S, Figueroa K, Kwan JY, Goldman J, Hunt A, Sampson J, Gutmann L, Pulst SM, Mitsumoto H, Kuo SH.

JAMA Neurol. 2013 Oct;70(10):1302-4.

28.

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G.

Diabetes Obes Metab. 2013 May;15(5):463-73. doi: 10.1111/dom.12090. Epub 2013 Mar 28.

29.

Mesial temporal lobe epilepsy in a patient with spinocerebellar ataxia type 13 (SCA13).

Bürk K, Strzelczyk A, Reif PS, Figueroa KP, Pulst SM, Zühlke C, Oertel WH, Hamer HM, Rosenow F.

Int J Neurosci. 2013 Apr;123(4):278-82. doi: 10.3109/00207454.2012.755180. Epub 2013 Jan 29.

PMID:
23215817
30.

Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study.

Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM.

Arch Neurol. 2012 Dec;69(12):1572-7. doi: 10.1001/archneurol.2012.2261.

PMID:
22945795
31.

JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.

Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP.

J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. Epub 2011 Apr 14.

32.

Frequency of KCNC3 DNA variants as causes of spinocerebellar ataxia 13 (SCA13).

Figueroa KP, Waters MF, Garibyan V, Bird TD, Gomez CM, Ranum LP, Minassian NA, Papazian DM, Pulst SM.

PLoS One. 2011 Mar 29;6(3):e17811. doi: 10.1371/journal.pone.0017811.

33.

Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard.

Figueroa KW, Suga H, Ehlert FJ.

Br J Pharmacol. 2010 Jul;160(6):1534-49. doi: 10.1111/j.1476-5381.2010.00810.x.

34.

One hundred years of histamine research.

Figueroa K, Shankley N.

Adv Exp Med Biol. 2010;709:1-9. Review.

PMID:
21618882
35.

Genetic variance in the spinocerebellar ataxia type 2 (ATXN2) gene in children with severe early onset obesity.

Figueroa KP, Farooqi S, Harrup K, Frank J, O'Rahilly S, Pulst SM.

PLoS One. 2009 Dec 14;4(12):e8280. doi: 10.1371/journal.pone.0008280.

36.

KCNC3: phenotype, mutations, channel biophysics-a study of 260 familial ataxia patients.

Figueroa KP, Minassian NA, Stevanin G, Waters M, Garibyan V, Forlani S, Strzelczyk A, Bürk K, Brice A, Dürr A, Papazian DM, Pulst SM.

Hum Mutat. 2010 Feb;31(2):191-6. doi: 10.1002/humu.21165.

37.

SOLUBLE CD40 LIGAND IN DEMENTIA.

Giunta B, Figueroa KP, Town T, Tan J.

Drugs Future. 2009 Apr 1;34(4):333-340.

38.

5-Hydroxytryptamine receptor assays.

Figueroa KW, Martin GR, Pulido-Rios MT.

Curr Protoc Pharmacol. 2009 Sep;Chapter 4:Unit4.19. doi: 10.1002/0471141755.ph0419s46.

PMID:
22294394
39.

Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors [corrected].

Kim DS, Figueroa KW, Li KW, Boroujerdi A, Yolo T, Luo ZD.

Pain. 2009 May;143(1-2):114-22. doi: 10.1016/j.pain.2009.02.006. Erratum in: Pain. 2009 Aug;144(3):345.

40.

Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes.

Figueroa KW, Griffin MT, Ehlert FJ.

J Pharmacol Exp Ther. 2009 Jan;328(1):331-42. doi: 10.1124/jpet.108.145219. Epub 2008 Sep 29.

41.

Use of acetylcholine mustard to study allosteric interactions at the M(2) muscarinic receptor.

Suga H, Figueroa KW, Ehlert FJ.

J Pharmacol Exp Ther. 2008 Nov;327(2):518-28. doi: 10.1124/jpet.108.141234. Epub 2008 Aug 5.

42.

Effective proximity retrieval by ordering permutations.

Chavez E, Figueroa K, Navarro G.

IEEE Trans Pattern Anal Mach Intell. 2008 Sep;30(9):1647-58. doi: 10.1109/TPAMI.2007.70815.

PMID:
18617721
43.

Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain.

Boroujerdi A, Kim HK, Lyu YS, Kim DS, Figueroa KW, Chung JM, Luo ZD.

Pain. 2008 Oct 15;139(2):358-66. doi: 10.1016/j.pain.2008.05.004. Epub 2008 Jun 20.

44.

3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.

Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP.

J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. Epub 2007 Aug 7.

45.

Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2.

Simon DK, Zheng K, Velázquez L, Santos N, Almaguer L, Figueroa KP, Pulst SM.

Arch Neurol. 2007 Jul;64(7):1042-4.

PMID:
17620498
46.

Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.

Griffin MT, Figueroa KW, Liller S, Ehlert FJ.

J Pharmacol Exp Ther. 2007 Jun;321(3):1193-207. Epub 2007 Mar 28.

47.

Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.

Waters MF, Minassian NA, Stevanin G, Figueroa KP, Bannister JP, Nolte D, Mock AF, Evidente VG, Fee DB, Müller U, Dürr A, Brice A, Papazian DM, Pulst SM.

Nat Genet. 2006 Apr;38(4):447-51. Epub 2006 Feb 26.

PMID:
16501573
48.
49.

Generation and characterization of Sca2 (ataxin-2) knockout mice.

Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst SM.

Biochem Biophys Res Commun. 2006 Jan 6;339(1):17-24. Epub 2005 Nov 8.

PMID:
16293225
50.

An autosomal dominant ataxia maps to 19q13: Allelic heterogeneity of SCA13 or novel locus?

Waters MF, Fee D, Figueroa KP, Nolte D, Müller U, Advincula J, Coon H, Evidente VG, Pulst SM.

Neurology. 2005 Oct 11;65(7):1111-3. Epub 2005 Aug 31.

PMID:
16135769

Supplemental Content

Loading ...
Support Center